<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02189005</url>
  </required_header>
  <id_info>
    <org_study_id>Precre/Nutra001/PMI13</org_study_id>
    <nct_id>NCT02189005</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy of PreCrea® on Subjects With Higher Than Normal Blood Sugar Levels</brief_title>
  <acronym>Precrea</acronym>
  <official_title>A Prospective, Double Blind, Placebo-Controlled, Randomized, Multicentric, Study to Evaluate the Efficacy and Safety of PreCrea®, a Twice-daily Dietary Supplement in People With Higher Than Normal Blood Sugar Levels.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joe Fenn</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PreEmptive Meds, Pvt. Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of PreCrea® on subjects with
      higher than normal blood sugar levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Prospective, Double Blind, Placebo-Controlled, Randomized, Multicentric, study to evaluate
      the efficacy and safety of PreCrea®, a twice-daily dietary supplement in people with higher
      than normal blood sugar levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Dietary Supplement PreCrea 600 mg twice-daily in lowering Hemoglobin A1c (Hb A1c) levels</measure>
    <time_frame>Day 1(Baseline) to Day 90 (End of Study)</time_frame>
    <description>Change in HbA1c % from baseline (Day 1) to end of supplementation/treatment after 90 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of Dietary Supplement PreCrea 600 mg twice-daily</measure>
    <time_frame>Day 1 (Baseline) to Day 90 (End of Study)</time_frame>
    <description>Measure changes in Renal Function Tests: Blood Urea Nitrogen (BUN) from baseline (Day 1) to end of study (Day 90); Serum Creatinine from baseline (Day 1) to end of study (Day 90)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Dietary Supplement PreCrea 600 mg twice-daily in lowering Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Day 1 (Baseline) to Day 90 (End of Study)</time_frame>
    <description>Change in FPG % from baseline (Day1) to end of supplementation/treatment after 90 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of Dietary Supplement PreCrea 600 mg twice-daily with Liver Function</measure>
    <time_frame>Baseline (Day 1) to End of Study (Day 90)</time_frame>
    <description>Measure changes in Liver Function Tests: Aspartate Aminotransferase (AST) from baseline (Day 1) to End of Study (Day 90); Alanine Aminotransferase (ALT) from baseline (Day1) to End of Study (Day 90); Alkanine Phosphatase (ALP) from baseline (Day1) to End of Study (Day 90</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Pre-Diabetes</condition>
  <condition>Hyperglycemia</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>PreCrea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study dietary supplement (Precrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 600 mg capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Study dietary supplement (PreCrea 600 mg capsules)</intervention_name>
    <description>Study dietary supplement (PreCrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification.</description>
    <arm_group_label>PreCrea</arm_group_label>
    <other_name>PreCrea, Natural Sugar Lowerig Supplement, Predisease</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo 600 mg capsules</arm_group_label>
    <other_name>Placebo 600mg capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years to ≤ 65 years

          2. Newly diagnosed Male or Female participants with higher than normal blood sugar levels
             (FPG &gt;100 mg/dL) on of Pre-Diabetes and Diabetes Mellitus during screening and not on
             any treatment

          3. Ability to understand and willingness to sign and date a written Informed Consent
             Document at the screening visit before any protocol- specific procedures are performed
             and willing to adhere to the protocol and entire trial procedures

        Exclusion Criteria:

          1. Subjects with Type 1 Diabetes Mellitus

          2. Participants on insulin therapy and other oral anti-diabetic agents or having
             uncontrolled diabetes.

          3. Stroke, myocardial infarction, coronary artery bypass graft (CABG) percutaneous
             transluminal coronary angioplasty (PTCA) or angina pectoris within the last 12 months.

          4. Cardiac status New York Heart Association class III-IV

          5. Uncontrolled blood pressure &gt; 150 mmhg systolic and &gt; 100 mmhg diastolic

          6. Impaired renal function as shown by but not limited to serum creatinine ≥ 1.5 mg/dl
             for males and ≥ 1.4 mg/dl for female

          7. Clinically significant peripheral edema

          8. Clinical evidence of active liver disease or serum alenine aminotransferase (ALT) or
             aspartate amino transferase (AST) 2.5 times the upper limit of the normal range (2.5 X
             ULN)

          9. Participants on steroid

         10. Pregnancy or lactating women

         11. Known hypersensitivity to any of the study drugs

         12. Any malignancy within the last 5 years, with exception of adequately treated basal or
             squamous cell carcinoma of the skin or adequately treated carcinoma insitu.

         13. Current addiction or current alcohol abuse or history of substance or alcohol abuse
             within the last 2 years

         14. Subject is the investigator or any sub-investigator, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved in the conduct of
             the protocol

         15. Mental condition rendering the subject unable to understand the nature, scope and
             possible consequences of the study. Subject unlikely to comply with protocol e.g.
             uncooperative attitude, inability to return for follow up visits and unlikelihood
             completing of the study.

         16. Any disease or condition that in the opinion of the investigator and/or sponsor may
             interfere with the completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dia Care- Diabetes Care and Hormone Clinic</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johns College and Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Totall Diabetes and Hormone Institution</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <zip>452010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhatia Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>411007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inamdar Multispeciality Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411040</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Care Centre</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2014</study_first_submitted>
  <study_first_submitted_qc>July 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2014</study_first_posted>
  <last_update_submitted>May 14, 2015</last_update_submitted>
  <last_update_submitted_qc>May 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>PreEmptive Meds, Pvt. Ltd</investigator_affiliation>
    <investigator_full_name>Joe Fenn</investigator_full_name>
    <investigator_title>Sponsor-Medical Director</investigator_title>
  </responsible_party>
  <keyword>High blood sugar</keyword>
  <keyword>High HbA1C</keyword>
  <keyword>hyperglycemia</keyword>
  <keyword>Pre-Diabetes</keyword>
  <keyword>Natural Supplement for Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

